TrialPath
COPD · Nashville

COPD clinical trials in Nashville

7 recruiting chronic obstructive pulmonary disease studies within range of Nashville. Click any trial for full eligibility criteria and contact info.

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

NCT06476132 · Lung Transplant
Recruiting

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.

PhasePhase 2
TypeInterventional
Age12 Years
WhereLos Angeles, California, United States + 11 more
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
▾Tap for details

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576 · Chronic Graft-versus-host-disease
Recruiting

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

PhasePhase 2
TypeInterventional
Age2 Years
WhereBirmingham, Alabama, United States + 120 more
SponsorSyndax Pharmaceuticals
▾Tap for details
Apply

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Recruiting

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.

PhasePhase 2
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 22 more
SponsorJohns Hopkins University
▾Tap for details
Apply

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050 · Graft-versus-host Disease (GVHD)
Recruiting

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

PhasePhase 3
TypeInterventional
Age18 Years
WherePalo Alto, California, United States + 29 more
SponsorIncyte Corporation
▾Tap for details
Apply

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511 · cGVHD
Recruiting

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 36 more
SponsorIncyte Corporation
▾Tap for details
Apply

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Recruiting

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

PhasePhase 3
TypeInterventional
Age40 Years – 80 Years
WhereChandler, Arizona, United States + 321 more
SponsorSanofi
▾Tap for details
Apply

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561 · Chronic Graft-Versus-Host Disease (cGVHD)
Recruiting

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

PhasePhase 2
TypeInterventional
Age18 Years
WhereDuarte, California, United States + 25 more
SponsorDeciphera Pharmaceuticals, LLC
▾Tap for details
Apply